| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.046 | 0.1 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |